Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.

The development of safe and effective vaccines against both bovine and human respiratory syncytial viruses (BRSV, HRSV) to be used in the presence of RSV-specific maternally-derived antibodies (MDA) remains a high priority in human and veterinary medicine. Herein, we present safety and efficacy resu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Krister Blodörn, Sara Hägglund, Jenna Fix, Catherine Dubuquoy, Boby Makabi-Panzu, Michelle Thom, Per Karlsson, Jean-Louis Roque, Erika Karlstam, John Pringle, Jean-François Eléouët, Sabine Riffault, Geraldine Taylor, Jean François Valarcher
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ee5dbf2882934f13b2c98eaea6b2fee4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.

Ejemplares similares